Olympian Clinical Research

OCTOBER 14, 2021

If you’re thinking about joining a clinical trial, there are many benefits you could look forward to. But how can you tell if clinical trials are right for you? We’ve outlined five reasons why joining a clinical trial might be in your best interest.

Clinical Trials 52

Clinical Trials Trials Doctors Therapies 52

Drug Discovery World

OCTOBER 16, 2023

This environment of research excellence, in turn, fosters R&D, innovation, spin-offs, start-ups, networking, collaboration and entrepreneurship, which sets a sturdy foundation that attracts funding, and creates an appealing work culture. billion in funding. Northern Ireland “Northern Ireland is a medtech super-hub,” says Saleko.

Drugs 190

Drugs Science Therapies Targeted Protein Degradation 190

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

The Pharma Data

JANUARY 12, 2021

a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric oncology clinical trial enrollment, announced today it has launched its SYNERGY-AI Oncology Clinical Trial Command Center (OCTCC) with the mission to disrupt and accelerate the clinical trial enrollment process.

Clinical Trials 52

Clinical Trials Trials Clinical Research Pharmaceutical Companies 52

The Pharma Data

MARCH 23, 2023

COPD is also associated with a significant health and economic burden due to recurrent acute exacerbations that require systemic corticosteroid treatment and/or lead to hospitalization or even death. Smoking is a key risk factor for COPD, but even individuals who quit smoking can still develop the disease. In the U.S.

Trials 40

Trials Disease Treatment Therapies 40

Drug Discovery World

JANUARY 26, 2024

In the first case of its kind, gene therapy has restored hearing in a patient in the United States. AK-OTOF is a gene therapy being developed for the treatment of sensorineural hearing loss due to mutations in the otoferlin gene (OTOF). “These initial results show that it may restore hearing better than many thought possible.”

Therapies 261

Therapies Clinical Trials Hospitals Trials 261

Alta Sciences

JANUARY 23, 2024

James joined Altasciences, having previously worked as Vice President of Research at Akron Children’s Hospital, and most recently as Vice President of Research Operations for Circuit Clinical. Julie-Ann Cabana Altasciences +1 514 601-9763 jcabana@altasciences.com Weight 15 Tags Clinical Trials

Clinical Pharmacology 40

Clinical Pharmacology Clinical Trials Clinical Research Hospitals 40

The Pharma Data

MARCH 17, 2022

Merck (NYSE: MRK), known as MSD outside the United States and Canada, the European Organisation for Research and Treatment of Cancer (EORTC) and the European Thoracic Oncology Platform (ETOP) today announced results from the pivotal Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS. About ETOP.

Therapies 52

Therapies Clinical Trials Disease Trials 52

Drug Discovery World

SEPTEMBER 28, 2022

Yet despite this, the biggest players in the global pharma sector are increasingly opening their doors to partnerships with AI and machine learning companies, cognisant of the potential benefits these could provide across broad therapy areas such as oncology, autoimmune and rare diseases. . How AI can streamline drug discovery .

Pharma Companies 130

Pharma Companies Hospitals Clinical Trials Drugs 130

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. Credit: NIH Right now, many U.S.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

The Pharma Data

JUNE 26, 2021

The Phase 3 AMEERA-6 study will evaluate the efficacy and safety of Sanofi’s amcenestrant vs tamoxifen for women with estrogen receptor-positive (ER+) breast cancer who were unable to continue their adjuvant aromatase inhibitor (AI) therapy. Adjuvant therapy helps prevent and delay the progression of disease into the later setting.

Clinical Trials 52

Clinical Trials International Trials Therapies 52

Drug Discovery World

JULY 3, 2024

The findings from a single-patient gene therapy trial in Canada show promise in halting the progression of spastic paraplegia type 50 (SPG50). The results of the groundbreaking clinical trial have been published in Nature Medicine. At 12 months after dosing, the therapy was well tolerated.

Therapies 163

Therapies Clinical Trials Virus Disease 163

Precision for Medicine

JUNE 26, 2023

Unraveling the complexity of manufacturing next-gen biologics is critical to the shared mission of accelerating patient access to new therapies,” said Chad Clark, President of Precision for Medicine. Bethesda, Md., For more information, visit projectfarma.com.

Science 40

Science Small Molecule Clinical Research Engineering 40

Agency IQ

NOVEMBER 3, 2023

regulatory landscape for probiotics and other microbiome-based therapies Probiotics, a type of microbiome-based therapy containing live micro-organisms, are broadly available on drug store and grocery store shelves, but the regulatory classifications for products containing the same micro-organism can differ dramatically.

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

AUGUST 30, 2021

There is currently a lack of therapies for ARDS associated with COVID-19. MADRID-COVID is a randomized clinical trial conducted in close collaboration between the CNIC and cardiology, ICU, pulmonology, and biobank services at FJD Hospital.

Clinical Trials 52

Clinical Trials Trials Drugs Hospitals 52

The Pharma Data

SEPTEMBER 11, 2020

Starpharma strived to release DEP remdesivir to allow for less frequent dosing and for use in non-hospital settings such as care homes. DEP remdesivir enables subcutaneous or under the skin injections rather than intravenous infusion, allowing for outpatient treatments and reducing the burden on hospitals. Saama Technologies, Inc. ,

Clinical Trials 52

Clinical Trials Pharma Companies Hospitals Trials 52

Drug Discovery World

OCTOBER 20, 2022

This is unsurprising – our drug discovery industry does, after all, centre itself around creating initiatives that leave no one behind, from cancer therapies to malaria vaccines. . Overview . According to the International Trade Administration’s market overview, anti-tumour agents brought in the largest sales in 2020 in Japan.

International 130

International Drugs Science Government 130

The Pharma Data

JANUARY 17, 2021

The NDA was built on data from the Phase III VICTORIA trial. The primary endpoint of the study was composite of time to first occurrence of heart failure hospitalization or cardiovascular death. The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

OCTOBER 22, 2020

It is the first antiviral treatment proven to help patients hospitalized with COVID-19 recover more quickly – a significant benefit for patients and their families, for healthcare providers and hospitals, and for society at large. This type of study reduces the potential for bias and provides the highest quality scientific evidence.

Science 52

Science Clinical Trials Hospitals FDA Approval 52

Olympian Clinical Research

JUNE 25, 2020

Environmental changes such as travel, hospitalization, new visitors, etc. Make time for soothing activities such as massage therapy, calming music, and reading. The post Identifying & Coping With Agitation In Alzheimer’s Dementia Patients appeared first on Olympian Clinical Research. Misperceived threats.

Nurses 78

Nurses Clinical Research Clinical Trials Hospitals 78

The Pharma Data

NOVEMBER 1, 2020

Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. Clinical Data Expected by End of Year. The clinical data from this trial is expected to available by the end of this year. Brazil has reported almost 5.5M

Clinical Trials 52

Clinical Trials Trials Medical Schools Hospitals 52

The Pharma Data

APRIL 17, 2021

TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs. First introduced in 2013, TECFIDERA has demonstrated a well-established safety and efficacy profile with more than 10 years of data from clinical trials and real-world experience.

Treatment 52

Treatment Clinical Trials Disease Trials 52

The Pharma Data

NOVEMBER 10, 2020

This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. NEW YORK and LONDON, Nov. NEW YORK and LONDON, Nov. and Europe. Dr. Howard L.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

NOVEMBER 8, 2020

First randomized clinical trial demonstrating that CTC count may help personalize treatment choices. Published in the November issue of JAMA Oncology , this is the first study to support clinical utility of CTC count in a randomized clinical trial. mL received hormone therapy.

Research 40

Research Clinical Trials Therapies Treatment 40

The Pharma Data

AUGUST 15, 2021

WELIREG Approved for Adult Patients With VHL Disease Who Require Therapy for Associated Renal Cell Carcinoma, Central Nervous System Hemangioblastomas, or Pancreatic Neuroendocrine Tumors, Not Requiring Immediate Surgery. inhibitor therapy approved in the U.S. WELIREG is the first HIF-2? As an inhibitor of HIF-2?,

Treatment 52

Treatment Disease Clinical Trials Therapies 52

The Pharma Data

DECEMBER 15, 2020

The Phase III trial evaluated the use of the diabetes vaccine Diamyd ® , an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. STOCKHOLM , Dec.

Drug Development 40

Drug Development Clinical Trials Vaccine Trials 40

The Pharma Data

SEPTEMBER 1, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE:BMY) today announced interim results from the Phase 3 open-label extension trial DAYBREAK, demonstrating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (MS). of participants in the trial, respectively.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

SEPTEMBER 7, 2021

This new indication was granted approval based on overall survival (OS) findings from the pivotal Phase 3 KEYNOTE-590 trial. Shen Lin, vice president, Clinical Oncology, Beijing Cancer Hospital and Peking University, and deputy director, Beijing Institute for Cancer Research. About KEYNOTE-590.

Treatment 52

Treatment Research Laboratories Packaging Laboratories 52

The Pharma Data

DECEMBER 16, 2020

The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. Last year, GSK announced positive results from a two-year clinical trial involving several hundred people with active lupus nephritis treated with Benlysta.

FDA Approval 52

FDA Approval FDA Clinical Trials Treatment 52

Drug Discovery World

FEBRUARY 26, 2024

Reece Armstrong speaks to Kathryn Golden , SVP Technical Operations and Manufacturing, bit.bio, about novel technologies, and methods to manufacture human cells for therapies so more patients can access these treatments. Cell therapies have emerged as transformative and potentially curative treatments across a range of disease areas.

Therapies 130

Therapies Treatment Engineering Disease 130

The Pharma Data

JANUARY 17, 2021

The service is expected to become operational in 2021 and will be available for clinical research and clinical care — starting with private patients, followed by expansion into the public healthcare system over time. “We This press release features multimedia. View the full release here: [link].

Clinical Trials 40

Clinical Trials FDA Approval Pharmaceutical Companies Treatment 40

Agency IQ

MARCH 1, 2024

There are also some product-specific bioequivalence guidelines open for comment, along with concept papers proposing the development of materials on the topics of biosimilar development and non-inferiority comparisons in clinical trials.

Regulations 40

Regulations Biosimilars Clinical Trials Production 40

The Pharma Data

JULY 29, 2021

Our flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “The Cell Therapy product sales increased 39% to $219 million for the second quarter 2021 compared to the same period in 2020.

Science 52

Science Production Treatment FDA 52

The Pharma Data

JUNE 28, 2021

. “Plaque psoriasis is a chronic autoimmune disease in which the immune system overproduces inflammatory proteins which results in red, scaly and thickened areas of skin,” said Dr. Jennifer Soung, dermatologist and Director of Clinical Research at Southern California Dermatology in Santa Ana, California.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

NIH Director's Blog: Drug Development

JULY 20, 2017

The first genetic mutation that causes CF was discovered by a collaborative effort between my own research lab at the University of Michigan, Ann Arbor, and colleagues at the Hospital for Sick Children in Toronto—more than 25 years ago [1].

Clinical Trials 52

Clinical Trials Small Molecule Disease Therapies 52

Drug Discovery World

JULY 1, 2024

million) over a five-year period for Healthy Lifestyle Before and During Pregnancy to Prevent Childhood Obesity (the PRE-STORK Trial). million) was awarded over a five-year period for the Pre-pregnancy Weight Loss and Reducing Childhood Overweight project (PREPARE CHILD), a randomised controlled trial. billion DKK ($11.97 million ($3.4

Disease 163

Disease International Research Science 163

Drug Discovery World

APRIL 11, 2024

The Program Committee Chairs commented: “It has been an educational, enlightening, and inspiring week of captivating cancer science and research. And thanks to the city of San Diego for its hospitality.” Research highlights Blacksmith Medicines announced preclinical data on its oncology programme targeting flap endonuclease 1 (FEN1).

Biochemical Assays 130

Biochemical Assays DNA Pharmacokinetics Science 130